Comparative Pharmacology
Head-to-head clinical analysis: EXTINA versus FEMSTAT 3.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXTINA versus FEMSTAT 3.
EXTINA vs FEMSTAT 3
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antifungal agent that inhibits the enzyme 14α-demethylase, blocking the conversion of lanosterol to ergosterol, an essential component of fungal cell membranes.
Butoconazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, preventing ergosterol synthesis and disrupting fungal cell membrane integrity.
2.5% to 3.5% solution applied topically twice daily for 4 weeks.
Intravaginal cream: 1 applicatorful (5 g of 2% butoconazole nitrate) intravaginally at bedtime for 3 consecutive days.
None Documented
None Documented
Terminal elimination half-life is approximately 24-32 hours in adults, allowing once-daily dosing. Half-life may be prolonged in patients with renal impairment.
The terminal elimination half-life of butoconazole following topical vaginal administration is approximately 21-24 hours. This prolonged half-life supports once-daily dosing for 3 days in the treatment of vulvovaginal candidiasis.
Primarily renal excretion of unchanged drug (approximately 80-90% of the absorbed dose), with minor hepatic metabolism and fecal elimination (<10%).
Following topical vaginal administration of butoconazole nitrate, approximately 5% of the dose is absorbed systemically. The absorbed fraction is primarily metabolized in the liver and excreted via the biliary/fecal route. Renal excretion accounts for less than 3% of the administered dose.
Category C
Category C
Antifungal
Antifungal